Agents that deactivated Kupffer cells and agents that induced HSP and NF-κB were mostly used for donor preconditioning, whereas the agents that prohibited neutrophil activation were administered during recipient treatment. This evidence concerns the gene NFKB1 and hereditary spastic paraplegia.